06:02 AM EST, 11/04/2026 (MT Newswires) -- Boule Diagnostics (BOUL.ST) will discontinue its instrument business as it shifts its focus to its more profitable consumables, service, and OEM Clinical Diagnostic Solutions, or OEM CDS, operations. The shutdown is expected to reduce Boule's expenses by 90 million kronor to 100 million kronor per year starting in 2028, according to a Wednesday release. It involves workforce reductions within the Diagnostics division, subject to negotiations with relevant trade unions. The diagnostics company added that the move will not impact its OEM CDS business and reagent production operations in Spånga, Sweden.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.